The Long-term Effect of Tianqi Capsule Interventions to Prevent Diabetes in the REDUCES Study: a 8-year Follow-up Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02848053|
Recruitment Status : Unknown
Verified October 2016 by Lian-fengmei, Guang'anmen Hospital of China Academy of Chinese Medical Sciences.
Recruitment status was: Not yet recruiting
First Posted : July 28, 2016
Last Update Posted : October 4, 2016
Objectives: This study is aimed to assess whether Tianqi Capsule interventions have a long-term effect on the risk of diabetes and provide evidence that early intervention by traditional Chinese medicine could delay the progression from impaired glucose tolerance to diabetes.
Study contents: 1.420 participants were followed up for 8 years to assess the long-term effect of Tianqi Capsule. Phone-call followed up was applied to investigate the status of impaired glucose tolerance and orthoglycemic survivors until the end of REDUCES study. 2.To participants that determined the status of glucose metabolism, a variety of ways were used to find the evidence of diagnosis of glucose metabolic status, such as glycemia laboratory sheets from normal hospitals, medical records, the use of antidiabetic drugs or insulin injection, etc. 3. To participants that undiagnosed the status of glucose metabolism, oral glucose tolerance test, blood pressure, weight and blood biochemical analysis were performed to assess the state of glucose metabolism. 4. Questionnaires were given to all the participants to investigate their condition of treatment, diet, exercise and other lifestyle.
|Condition or disease||Intervention/treatment|
|Impaired Glucose Tolerance Type 2 Diabetes Mellitus||Other: no intervention|
Study design: Perspective study Study drug: Tianqi CapsuleInclusion criteria: 1. Subjects have participated in the REDUCES study before; 2. Informed consent forms were needed to participants performed to blood test; 3. Laboratory sheets could be voluntary acquirement by participants that determined the status of glucose metabolism; 4.Subjects were not disabled, and could take care of themselves. 5. Subjects did not suffer the infectious disease.
Exclusion criteria: 1. Subjects did not participate the REDUCES study; 2. Subjects suffered serious mental illness; 3. Subjects suffered severe mental or cognitive impairment; 4. Subjects had a history of drug or alcohol dependence; 5. Subjects have participated in other drug clinical trials in the past 1 month.
Main outcome index: Incidence of diabetes. Secondary outcome index: Body mass index, fasting blood-glucose, postprandial blood sugar, blood lipids, blood pressure.
|Study Type :||Observational|
|Estimated Enrollment :||420 participants|
|Observational Model:||Case Control|
|Official Title:||The Long-term Effect of Tianqi Capsule Interventions to Prevent Diabetes in the REDUCES Study: a 8-year Follow-up Study|
|Study Start Date :||August 2016|
|Estimated Primary Completion Date :||November 2016|
|Estimated Study Completion Date :||November 2016|
used Tianqi Capsule in the REDUCES study
Other: no intervention
used placebo in the REDUCES study
Other: no intervention
- Incidence of diabetes [ Time Frame: 0 week ]
- Number of participants with abnormal body mass index values (in kg/m^2) [ Time Frame: 0 week ]
- Number of participants with abnormal Triglycerides values (in mmol/L) [ Time Frame: 0 week ]
- Number of participants with abnormal Cholesterol values (in mmol/L) [ Time Frame: 0 week ]
- Number of participants with abnormal Low density lipoprotein values (in mmol/L) [ Time Frame: 0 week ]
- Number of participants with abnormal High density lipoprotein values (in mmol/L) [ Time Frame: 0 week ]
- Number of participants with abnormal Systolic Blood Pressure values (in mmHg) [ Time Frame: 0 week ]
- Number of participants with abnormal Diastolic Blood Pressure values (in mmHg) [ Time Frame: 0 week ]
- Number of participants with abnormal blood glucose values (in mmol/L) [ Time Frame: 0 week ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02848053
|Contact: Fengmei Lian, PHDfirstname.lastname@example.org|
|Study Chair:||Xiaolin Tong, PHD||Guang`anmen Hospital of China Academy of Chinese Medical Sciences|